The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Subscribe To Our Newsletter & Stay Updated
